Search peptides, terms, sources/
Repair and regeneration

Thymosin beta-4

Also known as: Thymosin β4 · Tβ4 · Tb4

Natural 43-amino-acid peptide studied in eye and wound-healing trials. Not licensed in the UK. Trials were small with mixed results. It is not TB-500.

UK status and evidence last reviewed .

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Limited evidence (level 2 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

1 finding at this grade. 1 further finding at this grade showed no effect and is not counted. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Thymosin beta-4 is recorded as not licensed in the UK (checked 14 November 2026).

Best study type
Human trials4 human trials · 1 animal

What is Thymosin beta-4?

Thymosin beta-4 is a naturally occurring 43-amino-acid peptide that binds actin inside cells and has been studied for wound and eye-surface healing. It is not licensed in the UK, its human trials were small with mixed results, and a phase II dry-eye trial missed both primary endpoints; it is not the same molecule as TB-500, so its results are not evidence for TB-500.

Class
Full-length thymosin beta-4 (43 amino acids)
Origin
Endogenous
Research areas
Healing & Recovery
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does Thymosin beta-4 work?

Laboratory work attributes wound-healing and anti-inflammatory effects to thymosin beta-4, through support for the movement of skin and blood-vessel cells, more collagen laying-down and growth of new blood vessels. The authors of the venous ulcer trial call these suggested mechanisms, not settled ones. The human trials used full-length thymosin beta-4 as eye drops or a topical product, not TB-500.

The mechanism in more detail

Thymosin beta-4 is a 43-amino-acid peptide that occurs naturally in the body. The published trial reports describe a synthetic version of it. Laboratory work attributes wound-healing and anti-inflammatory effects to it, through support for the movement of skin and blood-vessel cells, more collagen laying-down, and growth of new blood vessels. The authors of the venous ulcer trial describe these as suggested mechanisms (“thought to work by”), not settled ones.

The key point on this page is the difference from TB-500. TB-500 is described in the literature as the acetylated seven-residue fragment Ac-LKKTETQ, taken from the active site of thymosin beta-4. A 2026 narrative review in orthopaedics states that TB-500 is often confused with full-length thymosin beta-4 and that no validated biological or clinical equivalence has been shown. A 2024 laboratory study notes that the biological effects of TB-500 itself had not been documented, and suggests that wound-healing activity seen in cell tests may come from a metabolite of TB-500 rather than from TB-500 itself.

The human trials on this page used full-length thymosin beta-4 as eye drops or a topical product, and one early safety study used an intravenous route. None of them tested TB-500. They cannot be used as evidence for TB-500.

Classification and structure

Names
Thymosin beta-4; Thymosin β4; Tβ4; Tb4; RGN-259 (eye drops); RGN-137 (topical formulation)
Class
Full-length thymosin beta-4 (43 amino acids)
Origin
Endogenous
Structure
Full-length peptide of 43 amino acids. TB-500 is a separate, seven-residue fragment (Ac-LKKTETQ).
Routes used in the research
Eye drops in the ophthalmic trials, a topical product in the venous ulcer trial, and intravenous administration in the Phase 1 healthy-volunteer study. This reflects study methodology, not a usage instruction.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Thymosin beta-4 has 6 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

6 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
32001

1 of the findings graded Limited showed no effect, so it is not counted in the evidence grade at the top of the page.

Neurotrophic keratopathy Phase III Limited

In a randomised, placebo-controlled, double-masked Phase III trial of RGN-259 eye drops in people with Stage 2 or 3 neurotrophic keratopathy (a nerve-related corneal disease), complete healing at 4 weeks occurred in 6 of 10 treated subjects versus 1 of 8 given placebo. That difference gave p = 0.0656, which is above the usual 0.05 threshold. The authors also reported other significant healing measures and better eye comfort scores in the treated group, and no significant adverse effects.

Study type
Human trial
Population
Human, Stage 2 or 3 neurotrophic keratopathy, 18 subjects in the healing comparison (10 RGN-259, 8 placebo)
Source
1 Sosne et al., 2022

Limitation: Very small trial.

Limitations in full

Very small trial. The headline 4-week complete-healing comparison did not reach the usual 0.05 threshold. Full-length thymosin beta-4 as eye drops, so it says nothing about TB-500. Read from the abstract record on Europe PMC; the abstract does not state which measure was the primary endpoint.

Dry eye Phase II, primary endpoints not met Limited No effect shown

In a single-centre, double-masked Phase II trial of RGN-259 eye drops in 72 adults with moderate to severe dry eye, neither primary endpoint (ocular discomfort and inferior corneal staining at day 29) differed significantly between groups. On secondary measures, discomfort scores on day 28 in the controlled adverse environment test were 27% lower with treatment than with placebo (P = 0.0244), and central and superior corneal staining also improved. No adverse events were reported.

Study type
Human trial
Population
Human adults with moderate to severe dry eye, n=72, single centre, 28 days of treatment
Source
2 Sosne et al., 2015

Limitation: Primary endpoints were not met.

Limitations in full

Primary endpoints were not met. The positive results are secondary measures from a single site. Eye drops of full-length thymosin beta-4, not TB-500.

Severe dry eye Phase II, 9 patients Preliminary

In a small, double-masked Phase II trial of RGN-259 eye drops at 2 US sites in 9 patients with severe dry eye, including dry eye linked to graft-versus-host disease, the treated eyes (12) showed 35.1% less ocular discomfort than vehicle-treated eyes (6) at day 56 (P = 0.0141), and total corneal staining fell 59.1% versus vehicle (P = 0.0108). Tear film breakup time and tear volume also improved.

Study type
Human trial
Population
Human, severe dry eye including graft-versus-host disease, 9 patients, 2 US sites
Source
3 Sosne et al., 2015

Limitation: Nine patients, analysed by eye (12 versus 6 eyes).

Limitations in full

Nine patients, analysed by eye (12 versus 6 eyes). Early-phase and not replicated in the sources reviewed. Eye drops, not TB-500.

RGN-137 venous ulcer Phase II Preliminary

In a Phase 2, double-blind, placebo-controlled trial with escalating strengths of a topical thymosin beta-4 product (RGN-137), 73 patients with venous stasis ulcers were randomised at 8 European sites. The authors judged the safety of all strengths acceptable and similar to placebo and reported that one of the tested strengths may have the potential to speed wound healing. Complete healing within 3 months occurred in about 25% of patients, mostly those with small to moderate wounds or mild to moderate severity.

Study type
Human trial
Population
Human, venous stasis ulcer patients, n=73, 8 European sites (5 Italy, 3 Poland)
Source
4 Guarnera et al., 2010

Limitation: Short report of a Phase 2 trial.

Limitations in full

Short report of a Phase 2 trial. The abstract gives no adverse-event counts and no placebo comparison figures for healing. No Phase 3 ulcer trial was found in this review. Topical full-length thymosin beta-4, not TB-500.

TB-500 is a seven-residue fragment, not the full peptide Not graded

A 2026 narrative review in orthopaedics describes TB-500 as a seven-amino-acid fragment of thymosin beta-4. It says the two are often confused and that no validated biological or clinical equivalence between them has been shown. The review also finds that thymosin beta-4's musculoskeletal evidence is limited to in-vitro and rodent studies.

Study type
Narrative review
Population
Narrative review of published literature; no new patients
Source
5 Tham et al., 2026

Limitation: Narrative review, ahead of print.

Limitations in full

Narrative review, ahead of print. Only the abstract could be read. It is context for the definition, not trial evidence.

What TB-500 is, in laboratory work Preliminary

A 2024 analytical study describes TB-500 as the acetylated peptide Ac-LKKTETQ, a seven-residue piece taken from the active site of thymosin beta-4. The authors state that the biological effects of TB-500 itself had not been documented. In rat and cell experiments, only one metabolite (Ac-LKKTE) showed a significant wound-healing effect compared with control, and the authors suggest that healing activity previously credited to TB-500 may come from that metabolite.

Study type
Animal
Population
In-vitro enzyme and cell systems, human serum, rat urine, fibroblast wound assay
Source
6 Rahaman et al., 2024

Limitation: Laboratory and rat work, with a cell wound assay.

Limitations in full

Laboratory and rat work, with a cell wound assay. It contains no human efficacy data. The metabolite suggestion is the authors' interpretation.

What safety findings have been reported?

2 safety findings are recorded for Thymosin beta-4. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Phase 1, 40 healthy volunteers

A randomised, placebo-controlled Phase 1 study gave intravenous synthetic thymosin beta-4 or placebo to 40 healthy adults in four cohorts of 10, as single and then repeated administrations over 14 days. Adverse events were infrequent and mild to moderate. The abstract reports no toxicity that limited further escalation and no serious adverse events. That is too few people to rule out rarer harms.

Source
7 Ruff et al., 2010

Eye-drop trials: few adverse events reported

The neurotrophic keratopathy Phase III trial reported no significant adverse effects with RGN-259 eye drops, and the 72-patient dry eye Phase II trial reported no adverse events. Neither abstract gives detailed adverse-event tables.

Source
2 Sosne et al., 2015

What is Thymosin beta-4's UK regulatory status?

Marketing authorisation
No marketing authorisation for thymosin beta-4 in the UK was found. A check of the MHRA Products database active substance index on 14 November 2026 found no entry for thymosin beta-4. The trial products RGN-259 (eye drops) and RGN-137 (topical) were investigational, and no regulator approval for either was located in this review.
Prescription status
Not applicable, no licensed UK product was found to classify.
Medicine class
Not classified as a licensed medicine.
MHRA position
No MHRA authorisation found. Whether a specific product is a medicinal product is a case-by-case MHRA determination under the Human Medicines Regulations 2012, based on presentation and claims made.
Authorised use
None.
Other restrictions
In sport, the WADA 2026 Prohibited List (in force from 1 January 2026) names thymosin beta-4 and its derivatives, for example TB-500, under S2.3, growth factors, prohibited at all times.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Thymosin beta-4 is recorded as not licensed in the UK (checked 14 November 2026).

References

8 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S (2022). 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. International Journal of Molecular SciencesRCT, Human clinical trial · DOI 10.3390/ijms24010554 · PMID 36613994 · Original ↗
  2. Sosne G, Ousler GW (2015). Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clinical OphthalmologyRCT, Human clinical trial · DOI 10.2147/opth.s80954 · PMID 26056426 · Original ↗
  3. Sosne G, Dunn SP, Kim C (2015). Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. CorneaRCT, Human clinical trial · DOI 10.1097/ico.0000000000000379 · PMID 25826322 · Original ↗
  4. Guarnera G, DeRosa A, Camerini R, and 8 European sites (2010). The effect of thymosin treatment of venous ulcers. Annals of the New York Academy of SciencesRCT, Human clinical trial · DOI 10.1111/j.1749-6632.2010.05490.x · PMID 20536470 · Original ↗
  5. Tham A, Hodgkins CW, Kennedy JG (2026). Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500. Journal of the American Academy of Orthopaedic SurgeonsNarrative review · DOI 10.5435/JAAOS-D-26-00049 · PMID 42937313 · Original ↗
  6. Rahaman KA, Muresan AR, Min H, Son J, Han HS, Kang MJ, Kwon OS (2024). Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. Journal of Chromatography BAnimal-preclinical · DOI 10.1016/j.jchromb.2024.124033 · PMID 38382158 · Original ↗
  7. Ruff D, Crockford D, Girardi G, Zhang Y (2010). A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Annals of the New York Academy of SciencesRCT, Human clinical trial · DOI 10.1111/j.1749-6632.2010.05474.x · PMID 20536472 · Original ↗
  8. Medicines and Healthcare products Regulatory Agency (MHRA) (2026). MHRA Products database: active substance index (A to Z), checked 14 November 2026. MHRA Products database · Original ↗

Questions about Thymosin beta-4

What is Thymosin beta-4?

Thymosin beta-4 is a naturally occurring 43-amino-acid peptide that binds actin inside cells and has been studied for wound and eye-surface healing. It is not licensed in the UK, its human trials were small with mixed results, and a phase II dry-eye trial missed both primary endpoints; it is not the same molecule as TB-500, so its results are not evidence for TB-500. Read what it is.

Is Thymosin beta-4 licensed in the UK?

PeptGuru records Thymosin beta-4's UK status as: Not licensed in the UK. No marketing authorisation for thymosin beta-4 in the UK was found. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Thymosin beta-4 show?

PeptGuru records 6 research findings for Thymosin beta-4: 4 from human trials, 1 from an animal study and 1 from a regulatory or other record. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Thymosin beta-4?

2 safety findings are recorded, including: phase 1, 40 healthy volunteers; eye-drop trials: few adverse events reported. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Thymosin beta-4?

All 8 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • New profile · Thymosin beta-4 added: 6 findings and 2 safety items, each checked against its published record, with UK status checked on the MHRA register.

How findings are graded: the grading method. All changes.

  • TB-500Thymosin Beta-4 fragment

    Short synthetic fragment linked to thymosin beta-4. Not licensed in the UK. No human trials of TB-500 itself were found; trials of the full-length protein are not evidence for it.

    Repair and regenerationAnimal studiesEvidence reviewed
    LimitedNot licensed in the UK
  • BPC-157Body Protection Compound-157

    Synthetic gastric-derived peptide studied in animal models of tissue healing. Not licensed in the UK; human evidence is one small uncontrolled study.

    Repair and regenerationHuman observationalEvidence reviewed
    LimitedNot licensed in the UK
  • GHK-CuCopper peptide GHK

    Copper-binding tripeptide studied for skin ageing and wound healing. Topical cosmetic use; no licensed injectable product in the UK.

    Repair and regenerationHuman trialsEvidence reviewed
    LimitedNot licensed in the UK

Compare Thymosin beta-4 with TB-500

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.